ASCO 2020: Nivolumab plus ipilimumab combination for previously treated kidney cancer
Results from the phase II FRACTION-RCC clinical trial to assess [...]
Combination PD-1 and PD-L1 inhibitors for kidney cancer are no more beneficial than PD-1 inhibitor alone
A recent phase II clinical trial has shown that combined [...]
Avelumab as a first- or second-line treatment for metastatic kidney cancer
A recent study looked at the efficacy and safety of [...]
Outcomes of metastatic kidney cancer patients treated with first-line immunotherapy and second-line VEGFR-TKI
The standard of care recommended for the treatment of patients [...]
